Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6

by Berkan-Kawińska, Aleksandra , Pabjan, Paweł , Jaroszewicz, Jerzy , Kłos, Krzysztof , Polanska, Joanna , Tomasiewicz, Krzysztof , Łapiński, Tadeusz , Piekarska, Anna , Bolewska, Beata , Flisiak, Robert , Kowalska, Justyna , Mozer-Lisewska, Iwona , Pawłowska, Małgorzata , Zarębska-Michaluk, Dorota , Leszczyński, Piotr , Tudrujek-Zdunek, Magdalena , Simon, Krzysztof , Rorat, Marta , Rogalska, Magdalena , Kozielewicz, Dorota

in Body mass index / Coronaviruses / COVID-19 / Cytokine storm / Drug dosages / Hospitalization / Laboratories / Medical prognosis / Monoclonal antibodies / Oxygen saturation / Respiratory diseases / Severe acute respiratory syndrome coronavirus 2 / Variables

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6

2021

Confirm

Do you wish to request the book?

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6

Berkan-Kawińska, Aleksandra,

Pabjan, Paweł,

Jaroszewicz, Jerzy,

Kłos, Krzysztof,

Polanska, Joanna,

Tomasiewicz, Krzysztof,

Łapiński, Tadeusz,

Piekarska, Anna,

Bolewska, Beata,

Flisiak, Robert,

Kowalska, Justyna,

Mozer-Lisewska, Iwona,

Pawłowska, Małgorzata,

Zarębska-Michaluk, Dorota,

Leszczyński, Piotr,

Tudrujek-Zdunek, Magdalena,

Simon, Krzysztof,

Rorat, Marta,

Rogalska, Magdalena,

Kozielewicz, Dorota

2021

Overview

Despite direct viral effect, the pathogenesis of coronavirus disease 2019 (COVID-19) includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore, tocilizumab (TOC), a monoclonal antibody against IL-6 receptors, was considered as a possible therapeutic option. Patients were selected from the SARSTer database, containing 2332 individuals with COVID-19. Current study included 825 adult patients with moderate to severe course. Analysis was performed in 170 patients treated with TOC and 655 with an alternative medication. The end-points of treatment effectiveness were death rate, need for mechanical ventilation, and clinical improvement. Patients treated with TOC were balanced compared to non-TOC regarding gender, age, BMI, and prevalence of coexisting conditions. Significant effect of TOC on death was demonstrated in patients with baseline IL-6 > 100 pg/mL (hazard ratio [HR]: 0.21, 95% confidence interval [CI]: 0.08–0.57). The best effectiveness of TOC was achieved in patients with a combination of baseline IL-6 > 100 pg/mL and either SpO2 ≤ 90% (HR: 0.07) or requiring oxygen supplementation (HR: 0.18). Tocilizumab administration in COVID-19 reduces mortality and speeds up clinical improvement in patients with a baseline concentration of IL-6 > 100 pg/mL, particularly if they need oxygen supplementation owing to the lower value of SpO2 ≤ 90%.

Share this book

Add to My Shelf

Publisher

MDPI AG,MDPI

Subject